Cargando…
Ginsenoside Rg2 Attenuated Trastuzumab-Induced Cardiotoxicity in Rats
AIM: Trastuzumab (TZM) is a monoclonal antibody drug for HER2-positive breast cancer by targeting epidermal growth factor 2, but it has significant cardiotoxicity. Ginsenoside Rg2 has shown a variety of biological activities. This study was aimed at investigating whether Rg2 attenuates TZM-induced c...
Autores principales: | Liu, Guang, Zhang, Jinli, Sun, Fangyi, Ma, Jingtao, Qi, Xiaoyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769853/ https://www.ncbi.nlm.nih.gov/pubmed/35071601 http://dx.doi.org/10.1155/2022/8866660 |
Ejemplares similares
-
Ginsenoside Rg2 protects cardiomyocytes against trastuzumab-induced toxicity by inducing autophagy
por: Liu, Guang, et al.
Publicado: (2021) -
Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy
por: Li, Lan, et al.
Publicado: (2017) -
Ginsenoside Rg1 Prevents Doxorubicin-Induced Cardiotoxicity through the Inhibition of Autophagy and Endoplasmic Reticulum Stress in Mice
por: Xu, Zhi-Meng, et al.
Publicado: (2018) -
Comparative Pharmacokinetics of Ginsenoside Rg(3) and Ginsenoside Rh(2) after Oral Administration of Ginsenoside Rg(3) in Normal and Walker 256 Tumor-bearing Rats
por: Fan, He, et al.
Publicado: (2016) -
Ginsenoside Rg1 attenuates liver injury induced by D-galactose in mice
por: Xiao, Ming-He, et al.
Publicado: (2018)